Answers are grounded in this paper and cite their sources.
Autoimmune GFAP astrocytopathy (GFAP-A) has several proposed biomarkers, but few are readily available in routine practice. This single-center retrospective case-control study evaluated CSF soluble IL-2R α (sIL-2R), a readily measurable marker of T-cell activation, as a clinically accessible marker reflecting CNS inflammatory activity in GFAP-A in the context of autoimmune encephalitis (AE). CSF sIL-2R-related parameters were measured in patients with GFAP-A, MOGAD with encephalitis, anti-NMDAR encephalitis, anti-LGI1 encephalitis, and non-inflammatory neurological diseases (NINDs). sIL-2R was measured using chemiluminescent enzyme immunoassay. CSF, CSF/serum sIL-2R quotient (QsIL-2R), sIL-2R index (QsIL-2R/Qalbumin), and Qalbumin were compared across the groups, and longitudinal changes were examined. CSF sIL-2R, QsIL-2R, sIL-2R index, and Qalbumin levels were elevated in patients with GFAP-A compared with those in patients with NINDs and other AE groups. CSF sIL-2R discriminated GFAP-A from other selected AE subtypes. CSF predominance of sIL-2R levels was characteristic of GFAP-A. In GFAP-A, sIL-2R quotient diagrams showed QsIL-2R elevations disproportionate to Qalbumin and CSF sIL-2R levels decreased following immunotherapy alongside clinical improvements. These findings suggest that CSF sIL-2R may complement existing biomarkers by supporting the identification of GFAP-A among patients with suspected AE after exclusion of mimics and by providing adjunctive information on treatment-responsive immune activity in GFAP-A.
No takes yet. Share an insight, caveat, or question.
Haruna et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: